Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
busulfan + dexamethasone
- Development stage
- Unknown
- Lead developer
- GreenJay Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination of busulfan, an alkylating agent, and dexamethasone, a corticosteroid. This combination is primarily used as part of conditioning regimens prior to hematopoietic stem cell transplantation (HSCT) for patients with hematological malignancies, particularly chronic myeloid leukemia. Busulfan damages DNA in rapidly dividing cells, while dexamethasone provides anti-inflammatory and immunosuppressive effects. When used together in transplantation protocols, dexamethasone helps prevent nausea and vomiting associated with high-dose busulfan chemotherapy.
02
Targets
DNAGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on busulfan + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on busulfan + dexamethasone.